Patents Assigned to University of Kansas
  • Publication number: 20220002251
    Abstract: The disclosure provides human toll-like receptor modulators of general Formula (II), wherein R1, R2, R3, R4, R5, R6, R7, R8 are defined herein.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 6, 2022
    Applicant: University of Kansas
    Inventors: Sunil A. David, Mallesh Beesu, Giuseppe Caruso, Alex Salyer
  • Patent number: 11186765
    Abstract: The disclosure is directed to polyelectrolyte complex nanoparticles that can be used to deliver agents deep into hydrocarbon reservoirs. Methods of making and using said polyelectrolyte complex nanoparticles are also provided.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: November 30, 2021
    Assignees: CONOCOPHILLIPS COMPANY, UNIVERSITY OF KANSAS
    Inventors: Ying-Ying Lin, Cory Berkland, Jenn-Tai Liang, Ahmad Moradi-Araghi, Terry M. Christian, Riley B. Needham, James H. Hedges, Min Cheng, Faye L. Scully, David R. Zornes
  • Patent number: 11173173
    Abstract: The disclosure provides methods of treating cancer by selectively inhibiting p-S552-?-catenin, p-T217-?-catenin, p-T332-?-catenin, and/or p-S675-?-catenin production and/or activity. Such methods also and/or limit cancer-initiating cells.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: November 16, 2021
    Assignees: UNIVERSITY OF CONNECTICUT, UNIVERSITY OF KANSAS, STOWERS INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Rajeswari Kasi, Linheng Li, Xiuling Lu, John M. Perry, Gurusingham Sitta Sittampalam, Anuradha Roy, Xi C. He
  • Patent number: 11162143
    Abstract: Methods for producing engineered exosomes and other vesicle-like biological targets, including allowing a target vesicle-like structure to react and bind with immunomagnetic particles; capturing the immunomagnetic particle/vesicle complex by applying a magnetic field; further engineering the captured vesicles by surface modifying with additional active moieties or internally loading with active agents; and releasing the engineered vesicle-like structures, such as by photolytically cleaving a linkage between the particle and engineered vesicle-like structures, thereby releasing intact vesicle-like structures which can act as delivery vehicles for therapeutic treatments.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: November 2, 2021
    Assignees: The University of Kansas, Kansas State University Research Foundation
    Inventor: Mei He
  • Patent number: 11160832
    Abstract: Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+Helios+eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: November 2, 2021
    Assignees: The Children's Mercy Hospital, The University of Kansas
    Inventors: Amara Seng, Ryan Fischer, Thomas Yankee, Mary Markiewicz, John Szarejko
  • Patent number: 11142775
    Abstract: Vectors having a nucleotide sequence having SEQ ID NO:1 or a nucleotide sequence having at least 85% identity to SEQ ID NO:1, or a portion thereof, that is capable of regulating bocaparvovirus replication, or vectors having the complement of the nucleotide sequence, and methods of using the vectors, are provided.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: October 12, 2021
    Assignees: University of Iowa Research Foundation, University of Kansas
    Inventors: Ziying Yan, John F. Engelhardt, Jianming Qiu, Zekun Wang
  • Patent number: 11136492
    Abstract: The invention is directed to polymers that self-crosslink at acidic pH or can be crosslinked by phenolic agents in brine. Such polymers have lower viscosity and can be pumped deep into reservoirs, where they will cross link in situ, thus increasing their viscosity and/or form a gel and blocking thief zones. Methods of making and using such polymers are also provided.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: October 5, 2021
    Assignees: University of Kansas, Conocophilllips Company
    Inventors: Huili Guan, Cory Berkland, Ahmad Moradi-Araghi, Jenn-Tai Liang, Terry M. Christian, Riley B. Needham, James H. Hedges, Min Cheng, Faye L. Scully
  • Patent number: 11130736
    Abstract: The disclosure provides human toll-like receptor modulators of general Formula (II), wherein R1, R2, R3, R4, R5, R6, R7, R8 are defined herein.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: September 28, 2021
    Assignee: University of Kansas
    Inventors: Sunil A. David, Mallesh Beesu, Giuseppe Caruso, Alex Salyer
  • Patent number: 11129656
    Abstract: Embodiments of the present invention relate to systems, methods, and apparatus for immobilizing and/or securing bone portions. Particularly, at least one embodiment involves a compact anti-rotation device that can secure adjacent bones and/or bone portions in a manner that prevents or limits relative rotational movement thereof.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: September 28, 2021
    Assignee: University of Kansas
    Inventors: Terence Edward McIff, Edward Bruce Toby
  • Patent number: 11110098
    Abstract: The present disclosure is directed, among other things, to the surprising and unexpected efficacy provided by select V2R antagonists in significantly reducing the cell proliferation levels of clear cell renal cell carcinoma. Thus, the present disclosure provides methods, uses, and medicaments that include such select V2R antagonists for utility in treating clear cell renal cell carcinoma.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: September 7, 2021
    Assignee: University of Kansas
    Inventor: Reena Rao
  • Patent number: 11098008
    Abstract: Provided herein are compounds of the formulas: wherein: n, X2, R3, R3?, R4, R4?, R5, R5?, R6, and R6? are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including diabetic peripheral neuropathy or cancer.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: August 24, 2021
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Brian S. J. Blagg, Rick T. Dobrowsky, Mercy Anyika
  • Patent number: 11045556
    Abstract: The present invention relates to novel therapeutic nanoparticles. In particular, the present invention is directed to nanoparticles associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) with angiogenesis-activating-agents, methods of synthesizing the same, devices or compositions comprising such nanoparticles, as well as systems and methods utilizing the nanoparticles (e.g., in therapeutic settings for enhancing and/or activating angiogenesis at targeted tissue region).
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 29, 2021
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, THE UNIVERSITY OF KANSAS
    Inventors: Steven R. Buchman, Mark Cohen, Alexis Donneys, Noah Nelson, Laird Forrest, Ti Zhang, Qiuhong Yang
  • Publication number: 20210186972
    Abstract: Disclosed are pharmaceutical formulations comprising a compound of formula (I): in which R1, R2, R3, and R4 are as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for treating pancreatic adenocarcinoma comprising administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and methods of detecting the change in expression levels of one or both of FoxA1 and FoxO6 in a pancreatic adenocarcinoma tumor sample from a mammal, wherein the mammal has been administered a compound of formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 15, 2019
    Publication date: June 24, 2021
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, University of Kansas, Northwestern University
    Inventors: Udo Rudloff, Serguei Kozlov, Juan Jose Marugan, Sui Huang, Samarjit Patnaik, John C. Braisted, Noel T. Southall, Marc Ferrer, Christopher Dextras, John Haslam, Michael Baltezor
  • Patent number: 11034679
    Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists of Formula I. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: June 15, 2021
    Assignees: UNIVERSITY OF KANSAS, VICTORIA LINK LIMITED
    Inventors: Thomas E. Prisinzano, Rachel Saylor Crowley, Bronwyn Maree Daken Kivell
  • Patent number: 11034883
    Abstract: The disclosure is directed to low molecular weight polyelectrolyte complex nanoparticles that can be used to deliver agents deep into hydrocarbon reservoirs. Methods of making and using said polyelectrolyte complex nanoparticles are also provided.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: June 15, 2021
    Assignees: THE UNIVERSITY OF KANSAS, CONOCOPHILLIPS COMPANY
    Inventors: Stephen J Johnson, Cory Berkland, Ahmad Moradi-Araghi, Jenn-Tai Liang, Terry M. Christian, Riley B. Needham, Min Cheng, Ying-Ying Lin, Andrew B. Woodside
  • Patent number: 11033437
    Abstract: A barrier system is provided for use in reducing infections associated with post-operative surgical incision and/or a percutaneous medical device, such as a catheter, that is disposed within the surgical incision. Such a barrier system may include: a barrier device having a skin-contacting surface and a catheter-receiving surface; and an adhesive composition configured for adhering to skin, the barrier device, and/or the catheter so as to form a barrier at or adjacent to an incision in the skin where the catheter is percutaneously inserted through the skin. A tensioning anchor and associated system of two or more tensioning anchors is provided for post-operative wound closure. A method for applying and removing the barrier device and tensioning anchors is also provided.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: June 15, 2021
    Assignee: University of Kansas
    Inventors: Stephen Clifford Waller, Dhaval Bhavsar
  • Patent number: 11033311
    Abstract: Embodiments of the present invention relate to systems, methods, and apparatus for immobilizing and/or securing bone portions. Particularly, at least one embodiment involves a compact anti-rotation device that can secure adjacent bones and/or bone portions in a manner that prevents or limits relative rotational movement thereof.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: June 15, 2021
    Assignee: University of Kansas
    Inventors: Terence Edward McIff, Edward Bruce Toby
  • Patent number: 11028041
    Abstract: The present technology provides compounds selective for the Grp94 isoform, as well as compositions including such compounds, that are useful for treatment of multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, prostate cancer, and/or glaucoma. Methods using the compounds are also provided.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: June 8, 2021
    Assignee: University of Kansas
    Inventors: Brian S. J. Blagg, Vincent Matthew Crowley
  • Patent number: 11000630
    Abstract: An implantable hydrogel precursor composition can include: a cross-linkable polymer matrix that is biocompatible; and a plurality of polymer particles in the cross-linkable polymer matrix. The cross-linkable polymer matrix can include a cross-linkable hyaluronic acid polymer that has cross-linkable functional groups. The hyaluronic acid polymer can be a methacrylated hyaluronic acid polymer. The methacrylated hyaluronic acid polymer can have a molecular weight from about 500 kDa to about 1.8 MDa. The polymer particles can include a cross-linked hyaluronic acid. The cross-linkable polymer matrix having the polymer particles has a yield stress. The cross-linkable polymer matrix having the polymer particles has shape retention at physiological temperatures. The composition can include live cells in the cross-linkable polymer matrix. The composition can include a biologically active agent in the cross-linkable polymer matrix.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: May 11, 2021
    Assignee: THE UNIVERSITY OF KANSAS
    Inventors: Michael Detamore, Emily Beck, Stevin Gehrke, Cory Berkland
  • Patent number: 10988506
    Abstract: Cyclic tetrapeptide stereochemical isomers of CJ-15,208, pharmaceutical compositions from such cyclic tetrapeptides, and methods of using such pharmaceutical compositions. The cyclic tetrapeptide compounds and pharmaceutical compositions disclosed herein are potent analgesics active in several pain models with generally minimal tolerance and reduced likelihood to induce addiction relative to other known opiates.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: April 27, 2021
    Assignee: University of Kansas
    Inventors: Jane V. Aldrich, S P Sanjeewa Nilendra Senadheera